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regression analyses were conducted to compare the time to ﬁ rst antipsychotic drug 
dispensing between the rivastigmine and donepezil groups. RESULTS: A total of 532 
patients receiving rivastigmine and 7,264 patients receiving donepezil were studied.
The donepezil group was slightly older (81.1 vs. 79.9 years; p  0.0044) with a greater 
proportion of women (59.4% vs. 53.2%; p  0.0053). The Kaplan-Meier analysis 
showed that 30 (5.6%) rivastigmine and 589 (8.1%) donepezil patients received anti-
psychotic medications (Log-rank p  0.0672). Multivariate adjustment showed that 
rivastigmine was associated with a statistically signiﬁ cant reduction in emergent use 
of antipsychotic drugs by 34% relative to donepezil (hazard ratio: 0.66; 95% CI:
0.46–0.96; p  0.0305). Among other statistically signiﬁ cant covariates, older age, 
lower drug dose, baseline depression and neuropsychiatric symptoms, and admission 
to inpatient long-term care facilities were associated with an increased likelihood of 
antipsychotic drug use. CONCLUSIONS: Based on real-world data from a large
cohort of antipsychotic-naïve patients with AD, rivastigmine was found to be associ-
ated with a signiﬁ cant reduction in the emergent use of antipsychotic drugs, compared
to donepezil. Prospective studies are needed to verify these ﬁ ndings.
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OBJECTIVES: We have initiated a project to identify statistically independent dimen-
sions of health services utilization in epilepsy. A desirable covariate for this analysis 
is the type of convulsive disorder. Here we report on the classiﬁ cation of epilepsy 
patients using insurance data. METHODS: We applied an iterative classiﬁ cation
technique to patients’ sequences of insurance claims for outpatient and inpatient ser-
vices, diagnostic procedures and drugs. The target population included 122,850 US
commercial insurance and Medicare supplement subscribers with a physician visit
diagnosis of ICD-9 345xx. We classiﬁ ed persons into the ICD-9 coding scheme (or as 
“not epilepsy”) by developing a family of rules corresponding to empirically observed 
claims patterns. We sampled patient histories in blocks of 50. Within each claims
history, a neuroepidemiologist looked for diagnosis, procedure and treatment patterns
that pointed to a clinical diagnosis, and added that pattern to the rule deﬁ ning a
diagnostic type. Removing classiﬁ ed patients, we sampled remaining claims histories
and repeated the process of classiﬁ cation and removal and sampling until 50 claims 
histories suggested no new classiﬁ cation rules. Remaining patients were tagged as
unclassiﬁ able. Finally, we reviewed samples of the classiﬁ ed patients to identify dis-
qualiﬁ cation criteria. RESULTS: The majority of patients are classiﬁ able and the
empirical classiﬁ cation rules “make sense” clinically (e.g. diagnostic changes are per-
mitted immediately if they follow a diagnostic procedure). A signiﬁ cant minority of 
cases of epilepsy have only nonspeciﬁ c treatment codes assigned. CONCLUSIONS:
There are clear examples of patients with different clinical subtypes of epilepsy in
claims data, and it will be possible to derive average utilization characteristics and
drivers for different types of epilepsy. Analysis of the dimensions of health care utiliza-
tion (combinations of drugs, procedures, physician and hospital) may yield further
insight into currently unclassiﬁ able cases and will provide sensitive measures of the
cost impact of new therapies.
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OBJECTIVES: Generic substitution might produce economic impacts beyond the
reduction in spending for new generic product, such as increased number of users,
and utilization of health care resources. The current study forecasts the economic
impact of generic entry of the antiepileptic drug (AED) topiramate into the settings of 
France, Germany, Italy, and the UK. METHODS: Health claims from Québec’s pro-
vincial health plan (RAMQ) from January 2006 to September 2008, and IMS Health 
data on European AED sales between 1998 and 2008 were used. Patient-level health
care utilization and costs in Canada were calculated during mutually-exclusive periods
of brand versus generic use of topiramate (Topamax). Annualized Canadian health
care costs were projected for periods of branded and generic use in each country 
(€2007/person-year). Using market-level sales, branded and generic topiramate utiliza-
tion were forecasted for 12 months following expected generic entry (September 
2009-September 2010) using autoregressive and panel-data regression models. The 
economic impact of generic entry was projected for each country, stratiﬁ ed into its
effect on market size, topiramate costs, and other health care costs. Budgetary conse-
quences for individual, private, and government payers were assessed. RESULTS:
Projected per-patient health care costs in G4 European countries, excluding topira-
mate, would be signiﬁ cantly higher during generic-use periods (adjusted cost differ-
ences per person-year: €706 to €815, p  0.001 for all comparisons) compared to
brand-use periods. Assuming mandatory generic substitution for all patients, predicted 
system-wide increases in total adjusted health care costs would range from 3.5% (UK)
to 24.4% (France) 1 year after generic entry. Increases in non-topiramate health care
costs (13.7% to 18.1%) would more than offset savings in topiramate costs (–6.3% 
to 13.8%) in France, Italy, and the UK. These impacts would be evenly distributed 
among payers of each country. CONCLUSIONS: Generic entry of topiramate in
Europe would represent a trade-off between reduced generic drug expenditures and 
increased health care costs.
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OBJECTIVES: To determine if dispending channel (specialty pharmacy versus retail) 
impacts medication adherence for patients receiving therapy for Multiple Sclerosis
(MS). METHODS: Retrospective pharmacy claims for MS patients were extracted for 
2007–2008. Patients were followed for 12 months from the index claim. Adherence 
was measured using a Medication possession ratio (MPR), with patients considered 
adherent if MPR q 80%. Propensity scoring was used in the sample selection. Differ-
ences of demographics were evaluated using the Wilcoxon signed-rank test for con-
tinuous variable and the chi-square test for the categorical variable. Generalize linear
regression was used to calculate the adjusted mean adherence. RESULTS: From a study 
population of 31,593 MS patients, a matched sample of 19,742 was chosen (9,871 in
the specialty and retail channel). There were no differences in demographics between 
the samples, with 76.19% female and mean age of 48.84. Overall comparison showed 
an average MPR of 89.94% for specialty and 84.08% for retail; with 81.52% of 
specialty patients adherent (MPR  80%) vs. 71.18% of retail patients. The results
were similar for each individual MS therapy. The following list the drug, and the 
percent of specialty and retail patients at least 80% adherent: Interferon beta-1a 
(Avonex) 87.49% vs. 78.13%, interferon beta-1a (Rebif) 80.97% vs. 75.50%, inter-
feron beta-1b 79.16% vs. 66.48%, glatiramer acetate 78.26% vs. 63.81%. (Average
MPRs for each drug available on the poster.) All comparisons were statistically sig-
niﬁ cant (P  .05). CONCLUSIONS: Patients who receive their MS medication from 
a specialty pharmacy are much more likely to be adherent than those who receive 
medication from a retail pharmacy. This is true across the broad category, as well as
each individual therapy. Specialty pharmacy offers enhanced patient counseling and 
clinical services, which may explain differences in adherence. Follow up studies will 
explore the impact of improved adherence on clinical and economic outcomes.
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OBJECTIVES: To review postmarketing surveillance data in order to examine reports 
of progressive multifocal leukoencephalopathy (PML) in patients using natalizumab 
for multiple sclerosis (MS) before and after the implementation of a natalizumab Risk 
Minimization Action Plan (RiskMAP) in the United States (US). METHODS: The 
Adverse Event Reporting System (AERS) database was searched for reports of serious 
adverse events of PML associated with natalizumab in MS patients during the pre- 
(November 23, 2004-February 28, 2005) and post-RiskMAP (July 2006-June 2008)
periods. AERS reports listing, 1) Tysabri or natalizumab as primary suspect drug; 2) 
events of PML; and 3) natalizumab-PML combination reports were extracted. Dupli-
cate reports and drug redundancies were excluded; in the event of duplicate case
reports, the report with the most recent date was used. Reports from foreign countries 
were excluded to focus the analysis on US-related events and to exclude variations 
due to different governmental requirements and national post-marketing surveillance 
systems. RESULTS: A total of 576,072 unduplicated reports were identiﬁ ed during 
the post-RiskMAP period in the US. A hands-on review of the reports of PML and
tysabri/natalizumab identiﬁ ed 41 and 1221 unduplicated US reports respectively, 
during the post-RiskMAP period. There were two conﬁ rmed cases (from previous lit-
erature) of PML associated with natalizumab before RiskMAP implementation and 
eight reported cases following RiskMAP implementation. The mean age of reported
natalizumab-PML cases post-RiskMAP was 50.6 years, and 7 of the cases (87.5%)
were in females. CONCLUSIONS: The extracted reports from the AERS indicate
continuing case reports for PML associated with natalizumab for MS during the post-
RiskMAP period. Although AERS is incapable of detecting the true frequency of an 
adverse event associated with a drug or assessing the actual causal relationship, these
reports of natalizumab-associated PML indicate that continued surveillance and
further epidemiologic study is necessary.
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OBJECTIVES: To evaluate the impact of the patient’s adherence to national guideline 
in the treatment costs. METHODS: A one-year (January 2007 to December 2007) 
retrospective database search was conducted to identify medication used, costs, patient 
adherence and provision. The source of data was the Ministry of Health public avail-
able database, called DATASUS. The study were conduct in four steps: 1) Determine 
the medicines codes in the public list; 2) Establish the relationships among drugs and
